Takeda Pharmaceutical Company Limited (TKPHF)

Theseus Pharmaceuticals Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	350,008	385,113	457,800	533,530	849,695	966,222
Cash & Short-Term Investments	350,008	385,113	457,800	533,530	849,695	966,222
Cash Growth	-56.48%	-15.88%	-14.19%	-37.21%	-12.06%	51.54%
Accounts Receivable	665,632	651,415	612,439	575,431	617,517	707,487
Other Receivables	13,899	73,839	85,171	106,262	106,860	105,227
Receivables	679,531	725,254	697,610	681,693	724,377	812,714
Inventory	1,240,676	1,217,349	1,209,869	986,457	853,167	753,881
Other Current Assets	242,907	193,476	193,301	196,276	166,403	180,076
Total Current Assets	2,513,122	2,521,192	2,558,580	2,397,956	2,593,642	2,712,893
Property, Plant & Equipment	1,956,269	1,968,209	1,989,777	1,691,229	1,582,800	1,453,917
Long-Term Investments	9,947	10,802	89,831	99,174	96,579	112,468
Goodwill	5,295,871	5,324,430	5,410,067	4,790,723	4,407,749	4,033,917
Other Intangible Assets	3,422,542	3,631,560	4,274,682	4,269,657	3,818,544	3,909,106
Long-Term Deferred Tax Assets	401,058	370,745	393,865	366,003	362,539	353,769
Other Long-Term Assets	405,728	421,406	391,990	343,008	316,165	336,223
Total Assets	14,004,537	14,248,344	15,108,792	13,957,750	13,178,018	12,912,293
Accounts Payable	421,308	308,450	319,955	307,453	295,934	232,105
Short-Term Debt	296,100	344,621	317,251	40,256	285	69
Current Portion of Long-Term Debt	75,043	204,318	50,000	299,344	203,708	22,084
Current Portion of Leases	-	64,443	66,208	59,623	53,877	50,187
Current Income Taxes Payable	150,965	133,497	109,906	232,377	200,918	145,203
Other Current Liabilities	1,226,170	1,451,192	1,449,783	1,542,887	1,391,008	1,323,528
Total Current Liabilities	2,169,586	2,506,521	2,313,103	2,481,940	2,145,730	1,773,176
Long-Term Debt	4,134,799	3,966,326	4,476,501	4,042,741	4,141,418	4,613,218
Long-Term Leases	535,165	508,882	553,431	419,728	411,361	386,225
Long-Term Deferred Tax Liabilities	33,514	35,153	113,777	270,620	451,511	542,852
Other Long-Term Liabilities	123,781	160,054	234,093	260,456	198,628	260,788
Total Liabilities	7,138,357	7,312,365	7,834,787	7,603,079	7,494,495	7,735,116
Common Stock	1,694,711	1,694,685	1,676,596	1,676,345	1,676,263	1,668,145
Additional Paid-In Capital	1,790,509	1,775,713	1,747,414	1,728,830	1,708,873	1,688,424
Retained Earnings	1,156,692	1,187,586	1,391,203	1,541,146	1,479,716	1,509,906
Treasury Stock	-124,124	-74,815	-51,259	-100,317	-116,007	-59,552
Comprehensive Income & Other	2,347,471	2,351,915	2,509,310	1,508,118	934,174	366,114
Total Common Equity	6,865,259	6,935,084	7,273,264	6,354,122	5,683,019	5,173,037
Minority Interest	921	895	741	549	504	4,140
Shareholders' Equity	6,866,180	6,935,979	7,274,005	6,354,671	5,683,523	5,177,177
Total Liabilities & Equity	14,004,537	14,248,344	15,108,792	13,957,750	13,178,018	12,912,293
Total Debt	5,041,107	5,088,590	5,463,391	4,861,692	4,810,649	5,071,783
Net Cash (Debt)	-4,691,099	-4,703,477	-5,005,591	-4,328,162	-3,960,954	-4,105,561
Net Cash Per Share	-2922.62	-2929.93	-3167.41	-2757.02	-2511.43	-2609.13
Filing Date Shares Outstanding	1,565	1,574	1,569	1,555	1,550	1,563
Total Common Shares Outstanding	1,565	1,574	1,569	1,555	1,550	1,563
Working Capital	343,536	14,671	245,477	-83,984	447,912	939,717
Book Value Per Share	4387.50	4407.01	4635.57	4087.49	3665.61	3308.93
Tangible Book Value	-1,853,154	-2,020,906	-2,411,485	-2,706,258	-2,543,274	-2,769,986
Tangible Book Value Per Share	-1184.33	-1284.22	-1536.94	-1740.89	-1640.44	-1771.82
Land	-	104,342	105,845	98,227	98,654	95,235
Buildings	-	955,045	937,156	826,523	763,460	670,609
Machinery	-	1,151,992	1,124,798	976,111	893,628	804,452
Construction In Progress	-	321,656	278,689	207,400	154,960	140,159

Source: S&P Global Market Intelligence. Standard template. Financial Sources.